Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study
Articolo
Data di Pubblicazione:
2007
Citazione:
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study / Piccaluga, P. P.; Malagola, M.; Random, M.; Arpinati, M.; Paolini, S.; Candoni, A.; Fanin, R.; Messa, E.; Pirrotta, M. T.; Lauria, F.; Visant, G.; Albert, D.; Rancati, F.; Vinaccia, V.; Russo, D.; Saglio, G.; Baccarani, M.; Martinelli, G.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:12(2007), pp. 1721-1722. [10.3324/haematol.11345]
Abstract:
We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
Tipologia CRIS:
Articolo su rivista
Keywords:
imatinib mesylate; acute myeloid leukemia; c-KIT; PDGFRB; targeted therapy
Elenco autori:
Piccaluga, P. P.; Malagola, M.; Random, M.; Arpinati, M.; Paolini, S.; Candoni, A.; Fanin, R.; Messa, E.; Pirrotta, M. T.; Lauria, F.; Visant, G.; Albert, D.; Rancati, F.; Vinaccia, V.; Russo, D.; Saglio, G.; Baccarani, M.; Martinelli, G.
Link alla scheda completa:
Link al Full Text:
Pubblicato in: